Isocitrate dehydrogenase mutations in gliomas.

Area of Science:

• Neuro-oncology
• Cancer Genetics
• Metabolic Oncology

Background:

• Significant advancements in understanding glioma genetics have occurred over the past decade.
• The discovery of mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) revolutionized glioma genetics in 2008.
• IDH1/2 mutations are prevalent in progressive gliomas and secondary glioblastomas (GBMs).

Purpose of the Study:

• To discuss mechanistic studies of IDH1/2 mutations in gliomas.
• To review the impact of IDH1/2 mutations on molecular classification.
• To explore the potential of IDH1/2 mutations in glioma therapy.

Main Methods:

• Literature review of mechanistic studies.
• Analysis of the role of IDH1/2 mutations in glioma pathogenesis.
• Review of molecular classification and therapeutic implications.

Main Results:

• IDH1/2 mutations confer neomorphic enzyme activity, converting α-ketoglutarate (αKG) to D-2-hydroxyglutarate (D2HG).
• D2HG inhibits αKG-dependent dioxygenases, promoting malignant transformation.
• Altered cellular epigenetics and blocked differentiation are consequences of D2HG accumulation.

Conclusions:

• IDH1/2 mutations are key drivers in glioma development and progression.
• Understanding these mutations is crucial for accurate molecular classification of gliomas.
• Targeting IDH1/2 mutations holds promise for novel glioma therapies.